293 related articles for article (PubMed ID: 18569395)
41. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
Ravandi F; Aribi A; O'Brien S; Faderl S; Jones D; Ferrajoli A; Huang X; York S; Pierce S; Wierda W; Kontoyiannis D; Verstovsek S; Pro B; Fayad L; Keating M; Kantarjian H
J Clin Oncol; 2009 Nov; 27(32):5425-30. PubMed ID: 19805674
[TBL] [Abstract][Full Text] [Related]
42. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin.
Frankel AE; Laver JH; Willingham MC; Burns LJ; Kersey JH; Vallera DA
Leuk Lymphoma; 1997 Jul; 26(3-4):287-98. PubMed ID: 9322891
[TBL] [Abstract][Full Text] [Related]
43. The emerging role of alemtuzumab in chronic lymphocytic leukemia.
Nabhan C
Clin Lymphoma Myeloma; 2005 Sep; 6(2):115-21. PubMed ID: 16231849
[TBL] [Abstract][Full Text] [Related]
44. Activity of alemtuzumab in patients with CD52-positive acute leukemia.
Tibes R; Keating MJ; Ferrajoli A; Wierda W; Ravandi F; Garcia-Manero G; O'Brien S; Cortes J; Verstovsek S; Browning ML; Faderl S
Cancer; 2006 Jun; 106(12):2645-51. PubMed ID: 16688777
[TBL] [Abstract][Full Text] [Related]
45. Monoclonal antibody therapy in lymphoid malignancies.
Hainsworth JD
Oncologist; 2000; 5(5):376-84. PubMed ID: 11040273
[TBL] [Abstract][Full Text] [Related]
46. Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
Boyd K; Dearden CE
Expert Rev Anticancer Ther; 2008 Apr; 8(4):525-33. PubMed ID: 18402519
[TBL] [Abstract][Full Text] [Related]
47. Antimouse CD52 monoclonal antibody inhibits established spontaneous colitis in IL-10-deficient mice.
Zhu WM; Li Y; Yu C; Li N; Li JS
Inflamm Bowel Dis; 2011 Jul; 17(7):E72-3. PubMed ID: 21538714
[No Abstract] [Full Text] [Related]
48. [Innovative antibody-therapies for malignant lymphomas].
Müller AM; Rawluk J; Thierry V; Brink I; Engelhardt M
Dtsch Med Wochenschr; 2005 Dec; 130(48):2783-8. PubMed ID: 16307409
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of alemtuzumab and gemcitabine in a patient with enteropathy-type T-cell lymphoma.
Soldini D; Mora O; Cavalli F; Zucca E; Mazzucchelli L
Br J Haematol; 2008 Jul; 142(3):484-6. PubMed ID: 18510686
[No Abstract] [Full Text] [Related]
50. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
[TBL] [Abstract][Full Text] [Related]
51. Management of advanced-stage peripheral T-cell lymphomas.
Kimby E
Curr Hematol Malig Rep; 2007 Oct; 2(4):242-8. PubMed ID: 20425376
[TBL] [Abstract][Full Text] [Related]
52. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
Jordan MB; McClain KL; Yan X; Hicks J; Jaffe R
Pediatr Blood Cancer; 2005 Mar; 44(3):251-4. PubMed ID: 15390358
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics of alemtuzumab and the relevance in clinical practice.
Elter T; Molnar I; Kuhlmann J; Hallek M; Wendtner C
Leuk Lymphoma; 2008 Dec; 49(12):2256-62. PubMed ID: 19052972
[TBL] [Abstract][Full Text] [Related]
54. Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study.
Kim SJ; Kim K; Kim BS; Suh C; Huh J; Ko YH; Kim WS
Ann Oncol; 2009 Feb; 20(2):390-2. PubMed ID: 19211502
[No Abstract] [Full Text] [Related]
55. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer.
Pulaski HL; Spahlinger G; Silva IA; McLean K; Kueck AS; Reynolds RK; Coukos G; Conejo-Garcia JR; Buckanovich RJ
J Transl Med; 2009 Jun; 7():49. PubMed ID: 19545375
[TBL] [Abstract][Full Text] [Related]
56. Monoclonal antibodies in the treatment of lymphoid leukemia.
O'Brien S; Giles FJ
Drugs Today (Barc); 2003 Jul; 39(7):541-50. PubMed ID: 12973402
[TBL] [Abstract][Full Text] [Related]
57. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
O'Brien SM; Kantarjian HM; Thomas DA; Cortes J; Giles FJ; Wierda WG; Koller CA; Ferrajoli A; Browning M; Lerner S; Albitar M; Keating MJ
Cancer; 2003 Dec; 98(12):2657-63. PubMed ID: 14669286
[TBL] [Abstract][Full Text] [Related]
58. Alemtuzumab in T-cell lymphoproliferative disorders.
Dearden CE; Matutes E
Best Pract Res Clin Haematol; 2006; 19(4):795-810. PubMed ID: 16997184
[TBL] [Abstract][Full Text] [Related]
59. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H).
Ru X; Liebman HA
Br J Haematol; 2003 Oct; 123(2):278-81. PubMed ID: 14531909
[TBL] [Abstract][Full Text] [Related]
60. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia.
Osterborg A; Mellstedt H; Keating M
Med Oncol; 2002; 19 Suppl():S21-6. PubMed ID: 12180488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]